Skip to main content
    G

    Grace Therapeutics, Inc. (GRCE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.72
    -0.03 (-1.71%)

    Market Cap: $36.81M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Grace Therapeutics, Inc. (GRCE) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Grace Therapeutics (GRCE) has a market cap of $36.81M and an enterprise value of $15.50M. Its share count is up 26.33% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 57.89% below the market cap, as cash exceeds debt.

    Market Cap$36.81M
    Enterprise Value$15.50M
    Latest price (Nov 17, 2026)$1.72

    Key Dates

    Last Earnings DateNov 12, 2026
    Fiscal Year EndMarch

    Share Statistics

    The share count rose 16.48% in the quarter ended Sep 30, 2026 and grew 32.22% a year over 2 years.

    Shares Outstanding20.12M
    Shares Change (YoY)+26.33%
    Shares Change (QoQ)+16.48%
    Share Count Growth (2Y CAGR)+32.22%

    Valuation Ratios

    P/B Ratio0.6x
    P/TBV Ratio1.8x

    Price Statistics

    The stock is down 43.79% over 52 weeks and trades 13.57% below its 50-day average.

    Beta (1Y)0.95
    52-Week Change-43.79%
    1-Month Change-8.51%
    3-Month Change-21.82%
    6-Month Change-20.00%
    Total Return (1Y)-43.79%
    Return vs SPY (1Y)-57.13%
    Max Drawdown (1Y)-66.47%
    Max Drawdown (3Y)-66.47%
    Sharpe Ratio (1Y)-0.73
    Correlation with SPY (1Y)0.16
    50-Day Average$1.99
    200-Day Average$2.71
    52-Week Range$1.67 to $5.18
    RSI (14 Days)35.0
    Average Volume (20 Days)112.82K

    Price chart

    Financial Position

    Current assets cover 13.61x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio13.61x
    Quick Ratio13.61x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -40.15% over the last 12 months, against a 5-year average of -31.34%.

    Return on Equity (ROE)-40.15%
    Return on Assets (ROA)-38.61%
    ROE (5Y Average)-31.34%
    ROA (5Y Average)-27.30%
    ROIC (5Y Average)-21.19%

    Scores

    GRCE has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Operating Income-$24.45M
    Pretax Income-$23.98M
    Net Income-$22.28M
    Reported EPS (TTM)-$1.29

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 96.15% of the $57.70M in total assets.

    Cash and Equivalents$21.31M
    Total Debt$0
    Net Cash$21.31M
    Net Cash Per Share$1.06
    Working Capital$20.35M
    Shareholder Equity$55.48M
    Book Value Per Share$2.76
    Tangible Book Value$19.75M
    Tangible Book Per Share$0.98
    Total Assets$57.70M
    Total Liabilities$2.22M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $0 of capital spending, operating cash flow left -$8.93M of free cash flow.

    Operating Cash Flow-$8.93M
    Capital Expenditures$0
    Free Cash Flow-$8.93M
    FCF Per Share-$0.42
    Depreciation and Amortization$8.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-19.93%
    Tangible Book Per Share Growth (2Y CAGR)-14.77%

    Revenue and profit by year

    Dividends and Yields

    GRCE does not pay a dividend. Its free cash flow yield is -25.81%.

    FCF Yield-25.81%
    Shareholder Yield0.00%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About GRCE

    What is GRCE's market cap?

    Grace Therapeutics has a market cap of $36.81M. Its enterprise value, which adds debt and subtracts cash, is $15.50M.

    How many shares of GRCE are outstanding?

    Grace Therapeutics has 20.12M shares outstanding. The count is up 26.33% from a year earlier.

    Does GRCE pay a dividend?

    No. Grace Therapeutics does not pay a dividend.

    How much debt does GRCE have?

    Grace Therapeutics has $0 of total debt and $21.31M of cash and equivalents, a net cash position of $21.31M.